Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat

Liver International

Volumn 34, Issue 4, 2014, Pages 521-534

  Yang, Ying Ying ^a,b   Liu, Ren Shyan ^a,b   Lee, Pei Chang ^a,b   Yeh, Yi Chen ^a,b   Huang, Yi Tsau ^b,c   Lee, Wei Ping ^a,b   Lee, Kuei Chuan ^a,b   Hsieh, Yun Cheng ^a,b   Lee, Fa Yauh ^a,b   Tan, Tat Wei ^a   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Angiogenesis; Brivanib; Sorafenib; SPECT PET CT scan

Indexed keywords

ALDOSTERONE; BRIVANIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUORODEOXYGLUCOSE F 18; HYDROXYPROLINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MANNITOL; NITRIC OXIDE; PHYTATE TC 99M; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SORAFENIB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BLOOD VOLUME; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DYE DILUTION CURVE; HEMATOCRIT; HEMODYNAMICS; HEPATIC VENOUS DYSREGULATION; HYPOTENSION; LEUKOCYTE; LEUKOCYTE ACTIVATION; LIVER BLOOD FLOW; LIVER DYSFUNCTION; MALE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MICROCIRCULATORY DYSFUNCTION; MICROVASCULATURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERIPHERAL HYPOTENSION; PLASMA VOLUME; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLANCHNIC VENOUS POOLING; TREATMENT DURATION; VENOUS STASIS;

ANGIOGENESIS; BRIVANIB; SORAFENIB; SPECT-PET-CT SCAN;

ALANINE; ANIMALS; ASCITES; CYTOKINES; DNA PRIMERS; FATTY LIVER; FIBROBLAST GROWTH FACTORS; MICROCIRCULATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PLATELET-DERIVED GROWTH FACTOR; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLANCHNIC CIRCULATION; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895783206     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12299     Document Type: Article

References (42)

1. McCuskey RS, Ito Y, Robertson GR, et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-93.
2. Francque S, Wamutu S, Chatterjee S, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splachnic vasodilatation and signs of a hyperdyanmic circulation in vitro and in vivo in a rat model. Liver Int 2010; 30: 365-75.
3. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212-23.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
5. Kitade M, Yoshiji H, Kojima H, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-91.
6. Yang YY, Tsai TH, Huang YT, et al. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinaemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology 2012; 55: 1540-50.
7. Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-94.
8. Hong F, Chou H, Fiel MI, Friedman SL. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 2013; 58: 257-64.
9. Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44.
10. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56.
11. D'Amico M, Mejías M, García-Pras E, et al. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1191-8.
12. Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4- (4-fluoro-2-methyl-1H-indol-5-yloxy)-5-Methyl Pyrrolo [2, 1-f] [1, 2, 4] Triaazin-6-yloxy) propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49: 2143-6.
13. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increase in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed leading to hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006; 290: G980-7.
14. Li Y, Liu H, Gaskari SA, et al. Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol 2008; 295: G252-9.
15. Li Y, Liu H, Gaskari SA, et al. Hepatic venous dysregulation contributes to blood volume pooling in cirrhotic rats. Gut 2006; 55: 1030-5.
16. Hoefs JC, Wang F, Kanei G, Braunstein P. The liver-spleen scan as a quantitatoive liver function test: correlation with liver severity at peritoneoscopy. Hepatology 1995; 22: 1113-21.
17. Huet PM, Chartrand R, Marleau D. Extrahepatic uptake of Tc-99m-phytate: its mechanism and significance in chronic liver disease. Gastroenterology 1980; 78: 76-80.
18. Chilton HM, Callahan RJ, Thrall JH. Radiopharmaceutical for cardiac imaging: myocardial infarction, perfusion, metabolism and ventricular function (blood pool). In: Swanson DP, Chilton HM, Thrall JH, eds. Pharmaceuticals in medical imaging. New York: Macmilan, 1990; 419-61.
19. 18F-FDG uptake in a model of inflammation: concentration A-mediated lymphocyte activation. J Nucl Med 2002; 43: 658-63.
20. 18F-FDG PET for semiquantitative evaluation of acute allograft rejection and immunosuppressive therapy efficacy in rat models of liver transplantation. J Nucl Med 2009; 50: 827-30.
21. Yang YY, Huang YT, Lin HC, et al. Thalidomide decreases intrahepatic resistance resistance in cirrhotic rats. Biochem Biophys Res Commun 2009; 380: 666-72.
22. Vollmar B, Siegmund S, Menger MD. An intravital fluorescence microscopic study of hepatic microvascular and cellular derangements in developing fibrosis in rats. Hepatology 1998; 27: 1544-53.
23. Yang M, Stapor PC, Peirce SM, Betancourt AM, Murfee WL. Rat mesentery exteriorization: a model for investigating the cellular dynamics involved in angiogenesis. J Vis Exp 2012; 63: e3954.
24. 2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376-381.
25. Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 induces the expression of vascular endothelial growth factor. J Bio Chem 1996; 271: 736-41.
26. Wieckowska A, Papouchado BG, Li ZZ, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-9.
27. Meng F, Wang K, Aoyama T, et al. Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-76.
28. Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. PNAS 2005; 102: 3389-94.
29. Lou SM, Li YM, Wang KM, et al. Expression of platelet-derived growth factor-BB in liver tissues of patients with chronic hepatitis B. World J Gastroenterol 2004; 10: 385-8.
30. Cao R, Brakenhielm E, Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and αβ receptors. The FASEB J 2002; 16: 1575-83.
31. Yu C, Wang F, Jin C, et al. Role of Fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 2003; 163: 1653-62.
32. Koolwijk P, van Erck MG, de Vree WJ, et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Bio Chem 1996; 132: 1177-88.
33. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1α promotes angiogenesis in vivo via VEGFR2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASAB J 2002; 16: 1471-73.
34. Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-65.
35. Kravetz D, Bosch J, Arderiu M, et al. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence the extent of portal-systemic shunting. Hepatology 1989; 9: 808-14.
36. Ludwig D, Schwarting K, Korbel CM, et al. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 1998; 28: 631-8.
37. Siringo S, Piscaglia F, Zironi G, et al. Influence of esophageal varices and spontaneous portal-systemic shunts on postprandial splanchnic hemodynamics. Am J Gastroenterol 2001; 96: 550-6.
38. Bellis L, Berzigotti A, Abraldes JG, et al. Low doses of isosorbide mononitrate attenuates the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003; 37: 378-84.
39. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intrahepatic-hepatic vascular response to both portal blood increase and methoxamine in cirrhotic rats. J Hepatol 2003; 39: 940-6.
40. Van Beers BE, Leconte I, Materne R, et al. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. Am J Roentgenol 2001; 176: 667-73.
41. Boswell CA, Ferl GZ, Mundo EE, et al. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS ONE 2011; 6: e17874-82.
42. Jimenez W, Martinez-Pardo A, Arroyo V, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 1985; 5: 245-50.